Effect of ANXA2 gene single nucleotide polymorphism (SNP) on the development of osteonecrosis in Indian sickle cell patient: A PCR-RFLP approach

Department of Hematology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110 029, India.
Indian journal of experimental biology (Impact Factor: 0.84). 07/2012; 50(7):455-8.
Source: PubMed


Osteonecrosis is a serious complication in sickle cell patients. The common sites of the necrosis are femoral head, head of the humerus and acetabulam. Annexin A2 (ANXA2) protein mainly functions in bone formation and bone resorption. Alteration of ANXA2 gene may affect the manifestations of osteonecrosis in the patients. PCR-RFLP is a common applicable technique for the detection of known mutation/polymorphisms. Here we are presenting application of the PCR-RFLP technique for determination of the ANXA2 gene single nucleotide polymorphism frequency and their clinical association among Indian sickle cell patients. Five known SNPs of ANXA2 gene (rs7170178, rs73435133, rs73418020, rs72746635 and rs73418025) were determined using the HpyCH4V, DdeI, HpyCH4III and Sau 961 restriction enzyme respectively. Restriction enzyme DdeI was common for rs73435133 and rs72746635 SNP. Only the rs7170178 SNP was detected among patient and control and the other four SNPs were absent in the studied groups. The frequency of ANXA2 gene rs7170178 SNP (A/G, G/G) was comparatively higher in sickle cell patients than controls and it was clinically associated with sickle cell osteonecrosis. The P value of heterozygotes (A/G) and homozygotes (G/G) genotypes were <0.001 and 0.001 respectively, which were highly significant. This study established the application of PCR-RFLP in detection of ANXA2 SNPs in sickle cell patients.


Available from: Ravi Ranjan, Jul 30, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Sickle cell disease (SCD) poses a considerable health burden in India. This review focuses on the recent initiatives to understand the variable phenotypes, the role of hydroxyurea in patients with the Asian haplotype and the feasibility of newborn screening, awareness and control programs. A systematic long follow up of patients in central India has documented the clinical events and the causes of significant morbidity and mortality. Fixed low dose hydroxyurea was sufficient for a clinical and hematological response in severe patients who had high baseline fetal hemoglobin (HbF) levels. Follow-up of birth cohorts of SCD babies initiated recently has shown that in central India babies clinically present with early and severe anemia, requiring blood transfusions, and septicemia, which are the most common complications, whereas babies from tribal communities in south Gujarat have no severe complications. Greater awareness has led to increasing requests for prenatal diagnosis. SCD in India is not uniformly mild despite high fetal hemoglobin levels. The benefits of comprehensive care and hydroxyurea therapy have been demonstrated. Newborn screening is acceptable and is beginning to throw light on the natural history of the disease. The central and state governments are now supporting the establishment of centers for the diagnosis of patients and comprehensive care.
    Current opinion in hematology 04/2014; 21(3). DOI:10.1097/MOH.0000000000000029 · 3.97 Impact Factor